TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05306015

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation based on brain-computer interface
Description: Before surgery, The nurses will teach and explain the methods and significance of meditation training. Let the patient be familiar with the function and background of this method, and explain the use of the headband during the operation, so that the patient believes that meditation training can relieve pain.~In surgery, Wear a brain-computer interface headband for the patient to collect EEG, monitor the patient's psychological changes, and provide real-time feedback.~The patient wears a Bluetooth headset, according to the patient's preferences, different types of music are selected, and voice playback guides the patient to prepare, relax muscles and regulate breathing.~APP judges the patient's meditation state based on EEG signals, and adjusts music, voice guidance.~The nurse will give personalized guidance based on the patient's specific situation and the EEG displayed on the APP to help the patient achieve a state of meditation and relaxation.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Give routine treatment and care, and increase or decrease the dose or adjust according to the patient's condition in accordance with the doctor's advice. Before surgery, we will introduce the level of medical care involved in the surgery and the equipment of our hospital. Inform the patient of the surgical process and possible pain, and explain in detail the cause, location and characteristics of the pain, including the time when the pain will appear and last. Instruct patients to stabilize their emotions and maintain a calm state of mind. As far as possible to meet the patient's intraoperative care needs, give psychological care, wear a headband to collect EEG signals, but do not intervene in mindfulness meditation.
Study: NCT06077786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06474
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Lu AG06474
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Lu AG06474
Description: Oral solution
Study: NCT05176704

Intervention type: DEVICE
Intervention: Eye-Tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.

Intervention type: DEVICE
Intervention: Eye-Tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.

Intervention type: DEVICE
Intervention: Eye-Tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
Study: NCT06549725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: software Lipidica
Description: The investigational medical device software (MDSW) Lipidica processes and analyses data inputs from the analysis of lipid profile in human plasma using an in-house in vitro diagnostic medical device.
Study: NCT05176704

Intervention type: DEVICE
Intervention: Eye-Tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.

Intervention type: DEVICE
Intervention: Eye-Tracking
Description: Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
Study: NCT06549725

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: software Lipidica
Description: The investigational medical device software (MDSW) Lipidica processes and analyses data inputs from the analysis of lipid profile in human plasma using an in-house in vitro diagnostic medical device.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic ultrasonography
Description: Endoscopic ultrasonography - maximum frequency: 3 times during the participation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance
Description: Magnetic resonance - maximum frequency: 3 times during the participation
Study: NCT06077786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Lu AG06474
Description: Oral solution
Study: NCT06549725

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: laboratory examination
Description: Lipidomic analysis, CA 19-9, CEA, HbA1c and hCG levels assessment (hCG only in women of childbearing potential in Arm 2)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: laboratory examination
Description: Lipidomic analysis, CA 19-9, CEA, HbA1c and hCG levels assessment (hCG only in women of childbearing potential in Arm 2)
Study: NCT06077786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule
Study: NCT06549725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: computed tomography - maximum frequency: 3 times during the participation
Study: NCT05215561

Intervention type: OTHER
Intervention: Cosentyx
Description: There is no treatment allocation. Patients administered Cosentyx by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT06362642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: First-in-class, oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Antifungal treatment that is a potent inhibitor of CYP3A4.
Study: NCT06160206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study: NCT06077786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule
Study: NCT06160206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT05696418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with a Mobile Bearing system.
Description: The prostheses will be cruciate scarifying cemented DePuy Synthes PFC Sigma with a Mobile Bearing system without resurfacing the patella.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with a Fixed Bearing system.
Description: The prostheses will be cruciate scarifying cemented DePuy Synthes PFC Sigma with a Fixed Bearing system without resurfacing the patella.
Study: NCT06525935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-388
Description: CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-388
Description: CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-388
Description: CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
Study: NCT06160206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Given IV
Study: NCT06338670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Osia 3 Sound Processor
Description: Osia 3 Sound Processor including sound processor magnets and Osia 3 Aqua +

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear™ Osia® 2 Sound Processor
Description: Osia® 2 Sound Processor
Study: NCT06525935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-388
Description: CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-388
Description: CT-388 will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be volume- matched and administered subcutaneously (SC) once weekly.
Study: NCT05646979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT group
Description: EFT protocol will be applied to the women in the experimental group who will have a cesarean section at 32-38 weeks of gestation.
Study: NCT06513416

Intervention type: PROCEDURE
Intervention: Elective upper abdominal surgery
Description: The included elderly patients are those who are preparing for elective upper abdominal surgery and the surgery time exceeds 2 hours.

Intervention type: PROCEDURE
Intervention: Elective upper abdominal surgery
Description: The included elderly patients are those who are preparing for elective upper abdominal surgery and the surgery time exceeds 2 hours.
Study: NCT06290024

Intervention type: DEVICE
Intervention: A multi-center clinical longitudinal study of neuropathic pain by collecting data on patients' brain physiology and cognitive function
Description: Using the use of pain visual analog scale (VAS), digital pain grading method (NRS), neuropathic pain assessment scale (DN4), sleep quality (Pittsburgh sleep quality index, Ascens insomnia scale), social support assessment scale (SSQ), Montreal cognitive assessment scale (MoCA), Barrett impulse scale (BIS), anxiety and depression score (GAD-7, PHQ-9), emotional tasks, cognitive function (N-back, time perception, delay-discount), electroencephalogram (EEG), near-infrared brain function imaging (fNIRS) and other indicators to study the dynamic changes of various factors in the process of acute pain.
Study: NCT05358249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: KRAS G12C inhibitor, oral
Study: NCT05358249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: KRAS G12C inhibitor, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: KRAS G12C inhibitor, oral
Study: NCT04830540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OOFOS Recovery Footwear
Description: The OOFOS shoes/ sandals are a commercially available footwear with a compliant, energy absorbing midsole material.
Study: NCT05358249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: MEK inhibitor, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK4/6 inhibitor, oral

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: EGFR inhibitor, intravenous
Study: NCT05783960

Intervention type: OTHER
Intervention: administration questionary
Description: Questionnaire will be compared to 24h sodium and potassium urinary excretion (reference). A Bayesian network and a multiple regression will be used to validate the questionary
Study: NCT06350513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animation movie, story book
Description: Animation movie: For this study, an animated film (Professor bumblebee animation) prepared for newly diagnosed children with type 1 diabetes will be shown in the experimental group. This is an approximately 10 minute film produced by Life for a children's center in New South Wales (DIABETES AUSTRALIA). The animated film will be translated into Turkish and sent to experts (specialists in the field of Children and Diabetes) for expert opinion. It will be shown to children after all permissions have been obtained following expert opinions. This animated movie is a guide to diabetes for children. Additionally, the storybook will be given as a gift for the children in the experimental group to read.~Story Book: It is an educational booklet version of the Professor Bumblebee animation translated into Turkish and illustrated. The aim here is to serve as an auxiliary tool for newly diagnosed T1D children to look at later and where they are confused.

Intervention type: OTHER
Group type: OTHER
Intervention: Animation movie, story book
Description: Animation movie: For this study, an animated film (Professor bumblebee animation) prepared for newly diagnosed children with type 1 diabetes will be shown in the experimental group. This is an approximately 10 minute film produced by Life for a children's center in New South Wales (DIABETES AUSTRALIA). The animated film will be translated into Turkish and sent to experts (specialists in the field of Children and Diabetes) for expert opinion. It will be shown to children after all permissions have been obtained following expert opinions. This animated movie is a guide to diabetes for children. Additionally, the storybook will be given as a gift for the children in the experimental group to read.~Story Book: It is an educational booklet version of the Professor Bumblebee animation translated into Turkish and illustrated. The aim here is to serve as an auxiliary tool for newly diagnosed T1D children to look at later and where they are confused.
Study: NCT06254326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTRNA-DC vaccines with GM-CSF
Description: Participants will receive up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem cells (HSCs)
Description: Participants will receive a single infusion of autologous CD34+ HSCs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTRNA-xALT
Description: Participants will receive a single infusion of ex vivo expanded tumor-reactive T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Td vaccine
Description: All patients will receive a full Td booster IM vaccine 4-24 hours prior to Vaccine #1 and vaccine site pretreatment with a one-fifth dose of Td intradermally, at the site of planned vaccine, 4-24 hours prior to vaccines #3, #5, #7 and #9.
Study: NCT05514444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4464
Description: MK-4464 administered as an IV infusion every three weeks according to allocation and dose escalation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4464
Description: MK-4464 administered as an IV infusion every three weeks according to allocation and dose escalation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4464
Description: MK-4464 administered as an IV infusion every three weeks according to allocation and dose escalation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg administered as an IV infusion every three weeks.
Study: NCT05753748

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Eradication Therapy
Description: Endoscopic eradication therapy is a procedure performed to destroy the precancerous cells at the bottom of your esophagus, so that healthy cells can grow in their place. It involves procedures to either remove precancerous tissue or burn it. These procedures are performed through the endoscope.
Study: NCT06294678

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Time of stem cell infusion
Description: Randomization of patients according to the time of stem cell infusion

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Time of stem cell infusion
Description: Randomization of patients according to the time of stem cell infusion
Study: NCT05381428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin suppository
Description: Control Group: Patients will be randomized to receive a 100 mg indomethacin suppository will be administered immediately before the endoscopic procedure (20-30 minutes) and saline infusion will be given as needed.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Indomethacin suppository and high-flow lactated ringer infusion combination
Description: Interventional group: Patients will be randomized to receive an indomethacin suppository that will be administered immediately before (20-30 minutes) the endoscopic procedure in combination with a lactated Ringer's infusion that will be administered with the following weight-based schedule: 3 cc/kg/h during ERCP, a bolus of 20 cc/kg after ERCP, and again 3 cc/kg/h for 8 hours after ERCP.
Study: NCT06150677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voluntary apnoea
Description: Static apneas at high lung volume with a density of 30 seconds, followed by a normal breath of 10 seconds (9 cycles of 30s apnea - 10s normal breathing, until completing the 6 minutes).
Study: NCT05376267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming,~A zero hour cooling duration (normothermia) treatment arm will be opened for enrollment if there is not an increase in the treatment effect across the durations. Alternatively, longer durations (84 or 96 hours) will be opened for enrollment if the treatment effects are increasing (rather than plateauing or decreasing) through 72 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming,~A zero hour cooling duration (normothermia) treatment arm will be opened for enrollment if there is not an increase in the treatment effect across the durations. Alternatively, longer durations (84 or 96 hours) will be opened for enrollment if the treatment effects are increasing (rather than plateauing or decreasing) through 72 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming,~A zero hour cooling duration (normothermia) treatment arm will be opened for enrollment if there is not an increase in the treatment effect across the durations. Alternatively, longer durations (84 or 96 hours) will be opened for enrollment if the treatment effects are increasing (rather than plateauing or decreasing) through 72 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming,~A zero hour cooling duration (normothermia) treatment arm will be opened for enrollment if there is not an increase in the treatment effect across the durations. Alternatively, longer durations (84 or 96 hours) will be opened for enrollment if the treatment effects are increasing (rather than plateauing or decreasing) through 72 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants will receive therapeutic hypothermia for the assigned number of hours with controlled rewarming,~A zero hour cooling duration (normothermia) treatment arm will be opened for enrollment if there is not an increase in the treatment effect across the durations. Alternatively, longer durations (84 or 96 hours) will be opened for enrollment if the treatment effects are increasing (rather than plateauing or decreasing) through 72 hours.
Study: NCT05670119

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured Training
Description: Structured catheter-related infection control training was prepared by using evidence-based information and receiving 10 expert opinions. This training will be given to the participants with a face-to-face PowerPoint presentation by the infection control nurse (researcher) and will also be presented as written material.
Study: NCT06559800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YourSkills: Cognitive behavioral therapy for children/youth with role-plays in virtual reality
Description: A program for children/youth with anger problems or aggressive behaviors based on social learning theory and cognitive behavior therapy (CBT), incorporating virtual reality (VR) when conducting brief role-plays. The program includes similar strategies as other CBT-oriented programs for anger problems, with the addition of VR for practicing skills.
Study: NCT05514444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg administered as an IV infusion every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-MK-4464
Description: 89ZR-MK-4464 administered as an IV infusion on C1D1.
Study: NCT06408519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (open-label)
Description: P-Tabletten weiss 10mm (Lichtenstein, Zentiva) pills 3x/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Ibuprofen pills 3x/day
Study: NCT06422286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser
Description: children will be allocated to the device then the gag reflex will be re-evaluated

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microcurrent stimulation
Description: children will be allocated to the device then the gag reflex will be re-evaluated

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: children will be allocated to a deactivated meridian pen
Study: NCT05925972

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plane block
Description: Plane block application in laparoscopic hysterectomies
Study: NCT05541198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure Injury Prevention Care Bundle
Description: 1. Risk Assessment~2. Skin Assessment~3. Skin Care~4. Positioning~5. Regulation of Nutrition and Liquid Management
Study: NCT05422469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept RC neurostimulator
Description: Medtronic SenSight directional DBS leads and implanted pulse generators (IPGs) will be implanted